ATC Group: C02AC Imidazoline receptor agonists

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C02AC in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C02 Antihypertensives
3 C02A Antiadrenergic agents, centrally acting
4 C02AC Imidazoline receptor agonists

Group C02AC contents

Code Title
C02AC01 Clonidine
C02AC02 Guanfacine
C02AC04 Tolonidine
C02AC05 Moxonidine
C02AC06 Rilmenidine

Active ingredients in C02AC

Active Ingredient

Clonidine has been shown to have both central and peripheral sites of action. With long-term treatment clonidine reduces the responsiveness of peripheral vessels to vasoconstrictor and vasodilator substances and to sympathetic nerve stimulation. Early in treatment, however, blood pressure reduction is associated with a central reduction of sympathetic outflow and increased vagal tone.

Guanfacine is a selective alpha2A-adrenergic receptor agonist in that it has 15-20 times higher affinity for this receptor subtype than for the alpha2B or alpha2C subtypes. Guanfacine is a non-stimulant. The mode of action of guanfacine in ADHD is not fully established.

Moxonidine has been shown to bind selectively to the I1-imidazoline receptors in the brain stem. These imidazoline-sensitive receptors are concentrated in the rostral ventrolateral medulla, an area which is of crucial importance for central control of the peripheral sympathetic nervous system. The result of this effect on the I1-imidazoline receptors has been apparent in reduced activity in the sympathetic nerves. (demonstrated for cardiac, splanchnic and renal sympathetic nerves).

Related product monographs

Document Type Information Source  
 CATAPRES Solution for injection MPI, EU: SmPC Health Products Regulatory Authority (IE)
 CATAPRES Tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)
 HYPERIUM Tablet MPI, EU: SmPC Medicines Authority (MT)
 INTUNIV Prolonged-release tablet MPI, EU: SmPC European Medicines Agency (EU)
 ONYDA Extended-release oral suspension MPI, US: SPL/PLR FDA, National Drug Code (US)
 PHYSIOTENS Film-coated tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)